A new webinar provides an overview of current guideline-recommended MI diagnostic pathways, spotlighting the role of high-sensitivity troponin I (hs-cTnI) in proven derived and validated algorithms* for Siemens Healthineers Atellica® IM and ADVIA Centaur® High-Sensitivity Troponin I assays:
- Hear from interventional cardiology and emergency medicine experts on the role hs-cTnI assay in clinical practice, the supporting guidelines and how these assays can be used to improve diagnostic pathways
- Learn how you can leverage the robust literature supporting the Siemens Healthineers hs-cTnI assay in your implementation
- Understand what other clinical considerations and tools you need to consider maximizing the impact hs-cTnI can have on your everyday clinical decision-making
Use this webinar to help support your clinicians on the choice of different pathways for the interpretation hs-cTnI into clinical practice and feel confident implementing the Atellica IM High-Sensitivity Troponin I Assay in their routine clinical practice.
*APACE, BACC, High-STEACS, RACING-MI, HIGH-US, and Japanese cohorts
The webinar is moderated by Sue Saville from European Medical Journal (EMJ), who will be joined by experts in the fields of interventional cardiology and emergency medicine discussing the use of hs-cTnI assays in clinical practice and how they can be used to improve diagnostic pathways.
Louise Cullen is a pre-eminent Staff Specialist in Emergency Medicine and a Clinical Trialist and Outcome Researcher in Acute Diseases at the Royal Brisbane and Women’s Hospital, Queensland, Australia, and works as a Professor at both Queensland University of Technology and the University of Queensland, Australia.
Nicholas Mills is the British Heart Foundation (BHF) Professor of Cardiology at the University of Edinburgh, UK; Consultant Interventional Cardiologist at the Royal Infirmary of Edinburgh, UK; Academic Lead and Senior Responsible Officer for the University of Edinburgh’s Health and Social Care Data Driven Innovation Hub, UK; and Chair of the ESC Working Group on Cardiac Biomarkers. Mills’ research group aims to use linked healthcare data to develop new approaches for the diagnosis and risk stratification of heart conditions and evaluate their impact on clinical outcomes in practice.